In the clinical setting of CRC, the use of monoclonal antibodies to block EGFR has demonstrated important clinical benefit exhibiting antitumor activity as monotherapy or in combination with chemotherapy and/or radiation. The gene discussed is EGFR; the disease is colorectal carcinoma.